{"id":1193,"date":"2008-04-01T12:07:00","date_gmt":"2008-04-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/idraparinux"},"modified":"2008-04-01T12:07:00","modified_gmt":"2008-04-01T10:07:00","slug":"idraparinux","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/idraparinux","title":{"rendered":"Idraparinux"},"content":{"rendered":"<p>In Tab. 1 unseres Hauptartikels \u201eNeue Antikoagulanzien\u201d (1) hatten wir zu Idraparinux als Bemerkung geschrieben: \u201eWegen h\u00e4ufiger Blutungen nicht weiter entwickelt\u201d. Dies bezog sich auf die unver\u00e4nderte Substanz als Arzneimittel. Jetzt hat uns Sanofi Aventis mitgeteilt, dass Idraparinux in chemisch ver\u00e4nderter Form (biotinyliert) als Idrabiotaparinux (durch Avidin zu antagonisieren) in drei Studien (EQUINOX, CASSIOPEA = [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Tab. 1 unseres Hauptartikels \u201eNeue Antikoagulanzien\u201d (1) hatten wir zu Idraparinux als Bemerkung geschrieben: \u201eWegen h\u00e4ufiger Blutungen nicht weiter entwickelt\u201d. Dies bezog sich auf die unver\u00e4nderte Substanz als Arzneimittel. Jetzt hat uns Sanofi Aventis mitgeteilt, dass Idraparinux in chemisch ver\u00e4nderter Form (biotinyliert) als Idrabiotaparinux (durch Avidin zu antagonisieren) in drei Studien (EQUINOX, CASSIOPEA = [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,2917,2916,2915,2918],"class_list":["post-1193","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-borealis-studie","tag-cassiopea-studie","tag-equinox-studie","tag-idrabiotaparinux"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1193"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1193\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}